Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Research Article

Ezetimibe Inhibits Cell Viability and Invasion by Suppressing PI3K/AKT Signaling Pathway in Human Osteosarcoma Cells

Author(s): Yong Zhang, Tongzhou Hu, Qiuyan Weng* and Jianning Luo*

Volume 21, Issue 11, 2024

Published on: 17 May, 2023

Page: [2008 - 2014] Pages: 7

DOI: 10.2174/1570180820666230418113909

Price: $65

Abstract

Introduction: Osteosarcoma is one of the most prevalent malignant bone tumors with a poor overall prognosis and mainly happens in children and adolescents. Current therapy strategies still possess a lot of limitations, and new and efficient strategies are required. Ezetimibe was previously reported to have its anti-tumor effect in various tumors, but the investigation of Ezetimibe on osteosarcoma is still limited.

Aims: This study explores whether ezetimibe could exert an anti-tumor effect on human osteosarcoma cell lines, U2OS, and Saos-2.

Methods: The effect of ezetimibe on the proliferation of osteosarcoma was explored by CCK-8 and colony formation assay. The role of ezetimibe on osteosarcoma cell migration and invasion was explored by wound healing assay and transwell assay. The role of ezetimibe on osteosarcoma cell apoptosis was explored by PI/Annexin V analysis. In addition, a western blot was performed to verify the phenotype.

Results: The flow cytometry assay indicated that ezetimibe could promote osteosarcoma apoptosis. Western blot assay further demonstrated the effect of ezetimibe on proliferation, migration, invasion and apoptosis- related proteins. Finally, the deep anti-tumor effect of ezetimibe contributed to suppressing the PI3K/AKT signaling pathway.

Conclusion: Present data indicated that ezetimibe has an antitumor effect on osteosarcoma and could be considered a future osteosarcoma treatment.

« Previous Next »
[1]
Ottaviani, G.; Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res., 2009, 152, 3-13.
[http://dx.doi.org/10.1007/978-1-4419-0284-9_1] [PMID: 20213383]
[2]
Grimer, R.J. Surgical options for children with osteosarcoma. Lancet Oncol., 2005, 6(2), 85-92.
[http://dx.doi.org/10.1016/S1470-2045(05)01734-1] [PMID: 15683817]
[3]
Gelberg, K.; Fitzgerald, E.; Hwang, S.; Dubrow, R. Growth and development and other risk factors for osteosarcoma in children and young adults. Int. J. Epidemiol., 1997, 26(2), 272-278.
[http://dx.doi.org/10.1093/ije/26.2.272] [PMID: 9169161]
[4]
Bacci, G.; Briccoli, A.; Rocca, M.; Ferrari, S.; Donati, D.; Longhi, A.; Bertoni, F.; Bacchini, P.; Giacomini, S.; Forni, C.; Manfrini, M.; Galletti, S. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: Recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann. Oncol., 2003, 14(7), 1126-1134.
[http://dx.doi.org/10.1093/annonc/mdg286] [PMID: 12853357]
[5]
Vara, J.Á.F.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; González-Barón, M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev., 2004, 30(2), 193-204.
[http://dx.doi.org/10.1016/j.ctrv.2003.07.007] [PMID: 15023437]
[6]
Zhang, J.; Yu, X.H.; Yan, Y.G.; Wang, C.; Wang, W.J. PI3K/Akt signaling in osteosarcoma. Clin. Chim. Acta, 2015, 444, 182-192.
[http://dx.doi.org/10.1016/j.cca.2014.12.041] [PMID: 25704303]
[7]
Chen, L.; Pei, H.; Lu, S.J.; Liu, Z.J.; Yan, L.; Zhao, X.M.; Hu, B.; Lu, H.G. SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-κB signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(3), 609-615.
[PMID: 29461588]
[8]
Solomon, K.R.; Pelton, K.; Boucher, K.; Joo, J.; Tully, C.; Zurakowski, D.; Schaffner, C.P.; Kim, J.; Freeman, M.R. Ezetimibe is an inhibitor of tumor angiogenesis. Am. J. Pathol., 2009, 174(3), 1017-1026.
[http://dx.doi.org/10.2353/ajpath.2009.080551] [PMID: 19179610]
[9]
Miura, K.; Ohnishi, H.; Morimoto, N.; Minami, S.; Ishioka, M.; Watanabe, S.; Tsukui, M.; Takaoka, Y.; Nomoto, H.; Isoda, N.; Yamamoto, H. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high‐fat diet. Cancer Sci., 2019, 110(2), 771-783.
[http://dx.doi.org/10.1111/cas.13902] [PMID: 30520543]
[10]
Wang, Y.; You, S.; Su, S.; Yeon, A.; Lo, E.; Kim, S. Cholesterol-lowering decreased mTOR complex 2 signaling and enhanced antitumor immunity. MedRxiv, 2021, 2021, 21250381.
[http://dx.doi.org/10.1101/2021.01.29.21250381]
[11]
Chen, G.; Li, J.; Wang, Z.; Liu, W. Ezetimibe protects against spinal cord injury by regulating autophagy and apoptosis through inactivation of PI3K/AKT/mTOR signaling. Am. J. Transl. Res., 2020, 12(6), 2685-2694.
[PMID: 32655800]
[12]
Qin, J.; Wang, L.; Liu, Z.; Zou, Y.; Fei, Y.; Liu, Z. Ezetimibe protects endothelial cells against oxidative stress through Akt/GSK-3β pathway. Curr. Med. Sci., 2018, 38(3), 398-404.
[http://dx.doi.org/10.1007/s11596-018-1892-3] [PMID: 30074204]
[13]
Czarnecka, A.M.; Synoradzki, K.; Firlej, W.; Bartnik, E.; Sobczuk, P.; Fiedorowicz, M.; Grieb, P.; Rutkowski, P. Molecular biology of osteosarcoma. Cancers, 2020, 12(8), 2130.
[http://dx.doi.org/10.3390/cancers12082130] [PMID: 32751922]
[14]
Harrison, D.J.; Geller, D.S.; Gill, J.D.; Lewis, V.O.; Gorlick, R. Current and future therapeutic approaches for osteosarcoma. Expert Rev. Anticancer Ther., 2018, 18(1), 39-50.
[http://dx.doi.org/10.1080/14737140.2018.1413939] [PMID: 29210294]
[15]
Takenaka, S.; Tamiya, H.; Wakamatsu, T.; Nakai, S.; Imura, Y.; Outani, H.; Yagi, T.; Kawai, A. Impact of surgical resection and reasons for poor prognosis of pelvic osteosarcoma based on the bone tumor registry in Japan. Cancers, 2021, 13(13), 3320.
[http://dx.doi.org/10.3390/cancers13133320] [PMID: 34282764]
[16]
Benjamin, R.S. Adjuvant and neoadjuvant chemotherapy for osteosarcoma: A historical perspective. In: Current Advances in Osteosarcoma; Kleinerman, E.S.; Gorlick, R., Eds.; Springer: Cham., 2020; Vol. 4257, pp. 1-10.
[http://dx.doi.org/10.1007/978-3-030-43032-0_1] [PMID: 32483726]
[17]
Hattinger, C.M.; Patrizio, M.P.; Fantoni, L.; Casotti, C.; Riganti, C.; Serra, M. Drug resistance in osteosarcoma: Emerging biomarkers, therapeutic targets and treatment strategies. Cancers, 2021, 13(12), 2878.
[http://dx.doi.org/10.3390/cancers13122878] [PMID: 34207685]
[18]
Prudowsky, Z.D.; Yustein, J.T. Recent insights into therapy resistance in osteosarcoma. Cancers, 2020, 13(1), 83.
[http://dx.doi.org/10.3390/cancers13010083] [PMID: 33396725]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy